WO1996028433A1 - Polyazacycloalkane compounds - Google Patents
Polyazacycloalkane compounds Download PDFInfo
- Publication number
- WO1996028433A1 WO1996028433A1 PCT/GB1996/000464 GB9600464W WO9628433A1 WO 1996028433 A1 WO1996028433 A1 WO 1996028433A1 GB 9600464 W GB9600464 W GB 9600464W WO 9628433 A1 WO9628433 A1 WO 9628433A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- chr
- formula
- groups
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Definitions
- This invention relates to novel polyazacycloalkane compounds, to processes for their preparation and to their use in the production of macrocyclic chelating agents.
- lanthanide metal ions especially Gd(III) and Dy(III) are among the most effective MR contrast enhancers and to ensure appropriate biodistribution and post-contrast bioelimination, they are administered in chelate complexes which have very high stability
- chelating agents used have a linear polyamine structure (eg. DTPA as in Schering's GdDTPA product Magnevist and DTPA-BMA as in Nycomed Imaging's GdDTPA-BMA product Omniscan), others have a macrocyclic polyamine structure, eg. DOTA as in
- the 1,4,7,10-tetraazacyclododecane (cyclen) polyamine skeleton of DOTA and HP-DO3A forms the basis for a range of particularly stable lanthanide-chelating macrocyclic chelants in which three or four of the ring nitrogens carry a pendant, ionizable metal coordinating group, eg. a carboxylic or phosphonic acid group. Since the lanthanide ions of interest are generally in the III state, cyclen-based chelants carrying three such acid groups offer the opportunity to produce charge-neutral or non-ionic chelate complexes. This is of importance since various side effects of contrast agent
- compositions are associated with hypertonicity and non-ionic contrast agents have a lower contribution to the overall osmolality of the composition.
- Cyclen is a key intermediate in the preparation of such macrocyclic chelating agents, with the ring nitrogens being appropriately substituted after macrocyclic ring formation has occurred.
- DOTA 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid
- cyclen leads to yield loss due to the formation of undesired N-substitution products.
- One approach to this is to mono-substitute cyclen before substituting the three remaining nitrogens; another is to start from a mono-substituted cyclen produced for example by
- the invention provides
- R is hydrogen, or a C 1-12 alkyl group optionally substituted by hydroxy, alkoxy or aryl groups or R is an amphiphilic aralkyl group comprising a N, S, O or P interrupted C 2-25 alkylene chain, e.g. a polyalkylene oxide chain or R provides a bridge to a second
- R is other than benzyl
- X is CHR 1 , or where R is hydrogen two X groups may each represent CO groups
- R 1 is
- any alkyl or alkylene moiety unless otherwise specified conveniently contains 1 to 12, preferably 1 to 6, carbons and any aryl group is preferably an optionally substituted phenyl group.
- amphiphilic chain R group is a group
- each L is an C 2-25 -alkylene linker wherein at least one CH 2 moiety is replaced by X 1 or a group X 1 (CH 2 CH 2 X 1 ) u (where u is a positive integer) such as X 1 CH 2 CH 2 X 1 , X 1 CH 2 CH 2 X 1 CH 2 CH 2 X 1 , X 1 CH 2 CH 2 X 1 CH 2 CH 2 X 1 CH 2 CH 2 X 1 , etc), and wherein L is optionally interrupted by a metabolizable group M but with the provisos that the terminus of L adjacent the cyclen ring is CH 2 and that the terminus of L adjacent Ar is X 1 or a CH 2 group adjacent or separated by one CH 2 from a group X 1 (thus for example the L-Ar linkage may be L 1 -X 1 -Ar, L 1 -CH 2 -Ar,
- each Ar is an aryl ring optionally substituted by or having fused thereto a further aryl ring;
- each AH is a protic acid group, preferably an oxyacid, e.g. a carbon, sulphur or phosphorus oxyacid or a salt thereof;
- each X 1 is O, S, NR 2 or PR 2 ;
- each R 2 is hydrogen, alkyl or aryl
- n is a positive integer for example 1, 2 or 3.
- carbonyl X groups are present, eg. as in the case where the compound is produced by a cyclization involving amines having N-attached LvCOCH 2 or LvCH 2 CO groups (where Lv is a leaving group such as a halogen atom), the compound can readily be reduced to the analogous compound of formula I wherein all X groups are CH 2 .
- the invention provides the use of compounds of formula I for the preparation of DO3A, N-substituted-1,4,7,10-tetraazacyclododecane-N',N",N"'-triacetic acids, and the phosphonic acid analogs.
- Lv is a leaving group (eg. a halogen atom or an OMs or OTs group) and R 1 is a group R other than hydrogen or where Lv-R 1 is a cyclic or unsaturated compound (eg. an epoxide) nucleophilically substitutable by an amine nitrogen to yield an N-attached R group other than hydrogen); (e) reacting a monoamine of formula XI
- R 2 is a group R or a nitrogen protecting group, eg. Ms
- R 2 is a group R or a nitrogen protecting group, eg. Ms
- the reagents of formulae II and VI can be prepared by reaction of ethylenediamine or diethylenetriamine with a benzylating agent, eg. a compound PhCH 2 Lv or with
- the reagent of formula III may be prepared by
- the iminodiacetic acid derivatives of formula VII can be prepared by conventional carboxylic acid activation procedures.
- steps (c) and (d) may be performed by conventional means as can the deprotection stages which may be required.
- Subsequent reaction of the compounds of formula I wherein each X is CHR 1 can be performed using standard amine substitution and debenzylation procedures.
- Debenzylation will preferably be effected by catalytic hydrogenation, eg. at a hydrogen pressure of 10 to 1000 psi, preferably 30-200 psi, a temperature of 0 to 200°C, preferably 25 to 120°C, and over a conventional
- hydrogeneration catalyst such as palladium/charcoal or platinum/C.
- Debenzylation is described by Rylander in "Catalytic hydrogeneration over platinum metals"
- the invention provides improved routes for high yield production of cyclen tri-substituted by acid groups and optionally mono-substituted by a desired further group, eg. DO3A HP-DO3A, or other hydroxyalkyl-DO3As, as well as DO3A-DO3A dimers.
- a desired further group eg. DO3A HP-DO3A, or other hydroxyalkyl-DO3As, as well as DO3A-DO3A dimers.
- the invention also provides a process for the production of DO3A or DO3A analog chelating agents, said process comprising the following steps
- N-alkylation step to introduce desired alkyl or substituted alkyl groups onto the macrocyclic skeleton can be performed using
- R 2 -Hal a halogen atom such as chlorine or bromine and R 2 is an alkyl group optionally substituted, for example by hydroxy or alkoxy groups or by chelant moieties, such as carboxyamide groups or carboxyl or phosphonic acid groups (optionally protected by ester groups)).
- the alkyl moiety in R 2 will conveniently contain 1 to 12 carbon atoms and any chelant moiety will preferably be on the alpha or beta carbon. If a protected chelant group is introduced in this fashion, it may subsequently be deprotected, for example by ester cleavage to make the group available for metallation.
- the macrocyclic chelating agents can be used in any order.
- metallated or unmetallated forms may for example be used as therapeutic agents, eg in the treatment of cancer.
- Metallation of the macrocyclic chelating agent may be effected by conventional methods, for example as
- ions of metals of atomic numbers 22 to 32, 42 to 44, 49 and 57 to 83 are especially preferred. ions of metals of atomic numbers 22 to 32, 42 to 44, 49 and 57 to 83, in
- the chelated metal species is conveniently a
- paramagnetic ion of a transition metal or a lanthanide preferably having an atomic number of 21 to 29, 42, 44 or 57 to 71.
- Complexes of Eu, Gd, Dy, Ho, Cr, Mn and Fe are especially preferred and Gd 3+ , Mn 2+ and Dy 3+ are particularly preferred ions.
- the paramagnetic metal species is conveniently non-radioactive as radioactivity is a characteristic which is neither required nor desirable.
- the metal is preferably a heavy metal such as a non-radioactive metal with an atomic number greater than 37, preferably greater than 50, for example Dy 3+ .
- the chelated metal species must of course be radioactive and any conventional complexable
- radioactive isotope such as 99m Tc or 111 ln for example may be used.
- the chelated metal may for example be 153 Sm, 67 Cu or 90 Y.
- EXAMPLE 1 N-benzylethylenediamine 1 and N,N'-dibenzylethylenediamine 2.
- a platinum group metal such as Ni, Ru or Pd
- a platinum group metal such as Ni, Ru or Pd
- Example 4(b) The volume of the CH 2 Cl 2 solution was 30 litres).
- TMG tetramethylguanidine
- EXAMPLE 8 1,14-bis-(1,4,7,10-tetraazacyclododecyl)-2,13dioxo-3,12-diaza-6,9-dioxatetradecane 9.
- EXAMPLE 10 1,14-bis-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl)-2,13-dioxo-3,12-diaza-6,9-dioxatetradecane 11.
- EXAMPLE 12 1,4,7-tetraazacyclododecane 12. (cyclen).
- Tribenzylcyclen 2.0g, 4.5mmol
- ethanol 50mL
- 10% Pd on carbon 1.0g
- EXAMPLE 13 1 ,4,7-tris(carboxymethyl-tert-butyl ester)-1,4,7,10-tetraazacyclododecane 14.
- EXAMPLE 1 4 1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane 15.
- EXAMPLE 17 [1,4,7-tris(carboxymethyl)-10-(10-(3,5-dicarboxyphenyl)-decyl)-1,4,7,10-tetraazacyclododecane]18.
- the alkylated tribenylcyclen intermediate is debenzylated as follows: A 100mL Autoclave pressure reactor is charged with ca. 10mmol of substrate, 50mL of ethanol and 3g of 10% Pd/C. The reactor is pressurized to 100-200psig with hydrogen for 3 hours at 80°C. The mixture is filtered to remove the catalyst and the filtrate is evaporated to give 1-[10-(3,5-dicarboxyphenyl)-decyl]-1,4,7,10-tetraazacyclododecane .
- the trihydroxybutyl tribenzylcyclen intermediate is de-benzylatyed as follows: A 100mL Autoclave pressure reactor is charged with ca.10mmol of substrate, 50mL of ethanol and 3g of 10% Pd/C. The reactor is pressurized to 100-200psig with hydrogen for 3 hours at 80°C. The mixture is filtered to remove the catalyst and the filtrate is evaporated to give 1-[2-(1,3,4-trihydroxybutyl)]-1,4,7,10-tetraazacyclododecane.
- a 2-L, 3-neck, round bottom flask equipped with an overhead stirrer, a reflux condenser, and a thermometer is charged with 375mL dimethylformamide (DMF) and 50g of K 2 CO 3 .
- the mixture is heated to 50°C.
- Ethylene diamine (0.2mols) diluted to 125mL with DMF and the product 4 from Example 3 diluted to 125mL with DMF are added to the warm potassium carbonate suspension in DMF over 1 ⁇ 2 hour.
- the resulting suspension is heated for 6 hours.
- About 1 ⁇ 2 of the DMF is removed by distillation at reduced pressure. 300mL of deionized water is added to the solution followed by 300mL CH 2 Cl 2 .
- a 1-L, 3-neck round bottom flask equipped with a reflux condenser, an overhead stirrer, and a nitrogen inlet is charged with 10.0g (0.02lmols) of 20 and 72mL of THF. The mixture is stirred under nitrogen. After cooling to 5-10°C, 176mL of 1.0 M BH 3 .THF is added to the
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU48391/96A AU4839196A (en) | 1995-03-10 | 1996-03-01 | Polyazacycloalkane compounds |
DE69621787T DE69621787T2 (en) | 1995-03-10 | 1996-03-01 | POLYAZACYCLOALKANVERBINDUNGEN |
EP96904204A EP0815091B1 (en) | 1995-03-10 | 1996-03-01 | Polyazacycloalkane compounds |
JP8527351A JP3059488B2 (en) | 1995-03-10 | 1996-03-01 | Polyazacycloalkane compounds |
NO974170A NO974170L (en) | 1995-03-10 | 1997-09-09 | Polyazacykloalkan compounds |
MXPA/A/1997/006900A MXPA97006900A (en) | 1995-03-10 | 1997-09-10 | Compounds of poliazacicloalc |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9504910.2 | 1995-03-10 | ||
GBGB9504910.2A GB9504910D0 (en) | 1995-03-10 | 1995-03-10 | Compounds |
US08/790,855 US5705637A (en) | 1995-03-10 | 1997-02-03 | Polyazacycloalkane compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996028433A1 true WO1996028433A1 (en) | 1996-09-19 |
Family
ID=26306651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1996/000464 WO1996028433A1 (en) | 1995-03-10 | 1996-03-01 | Polyazacycloalkane compounds |
Country Status (7)
Country | Link |
---|---|
US (3) | US5677446A (en) |
EP (1) | EP0815091B1 (en) |
AU (1) | AU4839196A (en) |
CA (1) | CA2214990A1 (en) |
GB (1) | GB9504910D0 (en) |
NO (1) | NO974170L (en) |
WO (1) | WO1996028433A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008026937A1 (en) | 2006-08-30 | 2008-03-06 | Ge Healthcare As | Method of dynamic nuclear polarisation (dnp) and compounds and compositions for use in the method |
FR2911340A1 (en) * | 2007-01-16 | 2008-07-18 | Commissariat Energie Atomique | Material, useful in ultrapurification of liquid and solid liquid extraction of metal pollutants dissolved in the effluents, comprises a polyazacycloalkane grafted on polypropylene fibers |
WO2008134289A2 (en) * | 2007-04-26 | 2008-11-06 | Mallinckrodt Inc. | High relaxivity coordinatively unsaturated lanthanide complexes |
WO2012059576A1 (en) | 2010-11-05 | 2012-05-10 | Bracco Imaging Spa | Cest systems exhibiting a concentration independent responsiveness |
WO2012140437A1 (en) | 2011-04-15 | 2012-10-18 | London Metropolitan University | Luminescent compounds, complexes and their uses |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4340809C2 (en) * | 1993-11-24 | 2000-08-03 | Schering Ag | 1.4,7,10-tetraazacyclododecane derivatives, pharmaceutical compositions containing them and process for their preparation |
IT1274038B (en) * | 1994-07-29 | 1997-07-14 | Bracco Spa | MACROCYCLIC CHELANTS THEIR CHELATES AND RELATED USES IN THE DIAGNOSTIC FIELD |
FR2725382B1 (en) * | 1994-10-05 | 1997-01-03 | Commissariat Energie Atomique | POLYAZACYCLOALCANES, TRI-, TETRA- OR PENTAAZAMACROCYCLIC COMPLEXES, PROCESS FOR MANUFACTURING SUCH SUBSTITUTED OR NON-SUBSTITUTED POLYAZACYCLOALCANES AND GRAFTS ON A SUPPORT AND USES OF POLYAZACYCLOALCANES |
ES2320323T3 (en) | 2000-09-29 | 2009-05-21 | Anormed Inc. | PROCEDURE FOR THE PREPARATION OF CYCLIC POLYAMIDS WITH N-1 PROTECTION CONTAINING NITROGEN ATOMS IN THE FORM OF RING N, AND PRODUCT AS OBTAINED. |
US20040034223A1 (en) * | 2002-02-07 | 2004-02-19 | Covalent Partners, Llc. | Amphiphilic molecular modules and constructs based thereon |
CN1646501A (en) * | 2002-02-07 | 2005-07-27 | 科瓦伦特合伙责任有限公司 | Nanofilm and membrane compositions |
US20040106741A1 (en) * | 2002-09-17 | 2004-06-03 | Kriesel Joshua W. | Nanofilm compositions with polymeric components |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001476A1 (en) * | 1987-08-12 | 1989-02-23 | Celltech Limited | Tetra-aza macrocycles and metal complexes thereof |
EP0374929A1 (en) * | 1988-12-22 | 1990-06-27 | The Dow Chemical Company | Process for preparing mono-n-alkylated polyazamacrocycles |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4885363A (en) * | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
EP0232751B1 (en) * | 1986-01-23 | 1991-09-11 | E.R. Squibb & Sons, Inc. | 1-substituted-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
US5271927A (en) * | 1986-02-13 | 1993-12-21 | Celltech Limited | Antibody conjugates with macrocyclic ligands |
US5064956A (en) * | 1987-06-24 | 1991-11-12 | The Dow Chemical Company | Process for preparing mono-n-alkylated polyazamacrocycles |
FR2654102B1 (en) * | 1989-11-09 | 1992-01-10 | Air Liquide | PROCESS FOR THE SYNTHESIS OF CYCLIC POLYAZOT DERIVATIVES. |
DE3938992A1 (en) * | 1989-11-21 | 1991-05-23 | Schering Ag | Cascade polymer-bound complex formers, their complexes and conjugates, process for their preparation and pharmaceutical compositions containing them |
US5236695A (en) * | 1989-11-27 | 1993-08-17 | Concat, Ltd. | MRI image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands |
IT1243801B (en) * | 1990-08-29 | 1994-06-28 | Bracco Ind Chimica Spa | INTERMEDIATES FOR CHELATING AGENTS WITH PRE-FIXED SYMMETRY, AND PROCEDURES FOR THEIR PREPARATION |
JPH0797340A (en) * | 1993-06-03 | 1995-04-11 | Terumo Corp | Mri contrast medium composition |
-
1995
- 1995-03-10 GB GBGB9504910.2A patent/GB9504910D0/en active Pending
- 1995-06-07 US US08/478,754 patent/US5677446A/en not_active Expired - Fee Related
- 1995-06-07 US US08/478,755 patent/US5631368A/en not_active Expired - Lifetime
-
1996
- 1996-03-01 CA CA002214990A patent/CA2214990A1/en not_active Abandoned
- 1996-03-01 AU AU48391/96A patent/AU4839196A/en not_active Abandoned
- 1996-03-01 EP EP96904204A patent/EP0815091B1/en not_active Expired - Lifetime
- 1996-03-01 WO PCT/GB1996/000464 patent/WO1996028433A1/en active IP Right Grant
-
1997
- 1997-02-03 US US08/790,855 patent/US5705637A/en not_active Expired - Fee Related
- 1997-09-09 NO NO974170A patent/NO974170L/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001476A1 (en) * | 1987-08-12 | 1989-02-23 | Celltech Limited | Tetra-aza macrocycles and metal complexes thereof |
EP0374929A1 (en) * | 1988-12-22 | 1990-06-27 | The Dow Chemical Company | Process for preparing mono-n-alkylated polyazamacrocycles |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008026937A1 (en) | 2006-08-30 | 2008-03-06 | Ge Healthcare As | Method of dynamic nuclear polarisation (dnp) and compounds and compositions for use in the method |
FR2911340A1 (en) * | 2007-01-16 | 2008-07-18 | Commissariat Energie Atomique | Material, useful in ultrapurification of liquid and solid liquid extraction of metal pollutants dissolved in the effluents, comprises a polyazacycloalkane grafted on polypropylene fibers |
WO2008099114A3 (en) * | 2007-01-16 | 2008-11-06 | Commissariat Energie Atomique | Material comprising polyazacycloalkanes grafted onto polypropylene fibres method for production thereof and method for removal of metal cations from a liquid |
RU2470951C2 (en) * | 2007-01-16 | 2012-12-27 | Коммиссариат А Л'Энержи Атомик | Material containing polyazacycloalkanes grafted on polypropylene fibre, method for production thereof and method of removing metal cations from liquid |
US8841384B2 (en) | 2007-01-16 | 2014-09-23 | Commissariat A L'energie Atomique | Material comprising polyazacycloalkanes, grafted on polypropylene fibres, its process of preparation, and process for removing metal cations from a liquid |
WO2008134289A2 (en) * | 2007-04-26 | 2008-11-06 | Mallinckrodt Inc. | High relaxivity coordinatively unsaturated lanthanide complexes |
WO2008134289A3 (en) * | 2007-04-26 | 2008-12-11 | Mallinckrodt Inc | High relaxivity coordinatively unsaturated lanthanide complexes |
WO2012059576A1 (en) | 2010-11-05 | 2012-05-10 | Bracco Imaging Spa | Cest systems exhibiting a concentration independent responsiveness |
WO2012140437A1 (en) | 2011-04-15 | 2012-10-18 | London Metropolitan University | Luminescent compounds, complexes and their uses |
Also Published As
Publication number | Publication date |
---|---|
NO974170L (en) | 1997-11-07 |
CA2214990A1 (en) | 1996-09-19 |
GB9504910D0 (en) | 1995-04-26 |
EP0815091B1 (en) | 2002-06-12 |
NO974170D0 (en) | 1997-09-09 |
US5705637A (en) | 1998-01-06 |
AU4839196A (en) | 1996-10-02 |
EP0815091A1 (en) | 1998-01-07 |
US5677446A (en) | 1997-10-14 |
US5631368A (en) | 1997-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0299795B1 (en) | Aminopolycarboxylic acids and derivatives thereof | |
FI93830C (en) | Nitrogen-containing cyclic ligands, processes for their preparation and their use for the preparation of metal complexes and diagnostic compositions containing these complexes | |
US5417960A (en) | Nitrogen-containing cyclic ligands, metallic complexes formed by these ligands, diagnostic compositions containing these complexes and process for the preparation of the ligands | |
US6177562B1 (en) | Chelated complexes of paramagnetic metals with low toxicity | |
US10781188B2 (en) | Contrast agents | |
Denat et al. | Strategies for the regioselective N-functionalization of tetraazacycloalkanes. From cyclam and cyclen towards more sophisticated molecules | |
EP0815091B1 (en) | Polyazacycloalkane compounds | |
IE67643B1 (en) | 1,4,7,10-tetraazacyclodedecane butyltriols processes for their production and pharmaceutical agents containing them | |
US5439668A (en) | Heterocyclic chelating agents | |
JP3128137B2 (en) | Method for producing tetraazacycloalkane and tricyclic compound used in this method | |
IE892335L (en) | Macrocyclic polyaza compounds containing 5 or 6 rings,¹process for producing them and pharmaceutical media¹containing them | |
AU7060291A (en) | Chelants | |
EP3442949B1 (en) | Contrast agents | |
US6048979A (en) | Preparation of N-arylmethyl aziridine derivatives, 1,4,7,10-tetraazacyclododecane derivatives obtained therefrom and N-arylmethyl-ethanol-amine sulphonate esters as intermediates | |
HUT74592A (en) | Polyazacycloalkanes as dichelants | |
JP3059488B2 (en) | Polyazacycloalkane compounds | |
JPH09507837A (en) | Method for producing polyaza macrocycle | |
MXPA97006900A (en) | Compounds of poliazacicloalc | |
WO1990008134A1 (en) | Chelating agent derivatives | |
KR19980702879A (en) | N-arylmethyl aziridine derivatives, 1,4,7,10- tetraazacyclododecane derivatives obtained therefrom and a method for producing N-arylmethylethanolaminesulfonate esters as intermediates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96193738.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2214990 Country of ref document: CA Ref document number: 2214990 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/006900 Country of ref document: MX Ref document number: 1019970706336 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996904204 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996904204 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970706336 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019970706336 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996904204 Country of ref document: EP |